⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTOR News
Citius Oncology, Inc. Common Stock
Form 8-K
sec.gov
CTOR
CTXR
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
prnewswire.com
CTXR
CTOR
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTOR
CTXR
Form 8-K
sec.gov
CTXR
CTOR
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
prnewswire.com
CTXR
CTOR
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTOR
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
prnewswire.com
CTOR
Form 8-K
sec.gov
CTOR
CTXR